Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks


Disclosures: Octapharma, the maker of Omniplasma, was shown a version of this manuscript.

Contributions: - J. van der Bom and M. Schipperus (PhD advisors), and N. Saadah (PhD student) conceived the study - N. Saadah performed the analysis and wrote the manuscript under guidance from J. van der Bom and M. Schipperus - J. van der Bom provided clinical and epidemiological review of the manuscript - J. Wiersum-Osselton and M. Schipperus provided clinical and haemovigilance review of the manuscript - M. van Kraaij provided clinical and blood product usage review of the manuscript - C. Caram-Deelder confirmed all results via independent parallel analysis and provided statistical review of the manuscript - E. Beckers, A. Leyte, J. Rondeel, K. de Vooght, F. Weerkamp, and J.J. Zwaginga provided data from the six participating hospitals and clinical review of the manuscript.